checkAd
    Startseite > Aktien > OSE Immunotherapeutics > Nachrichten
    OSE Immunotherapeutics Aktie
    7,5150
     
    EUR
    +0,80 %
    +0,0600 EUR
    Letzter Kurs 16.05.24 Lang & Schwarz
    7,5000
     
    EUR
    208 STK
    Geldkurs 16.05.24
    7,5300
     
    EUR
    208 STK
    Briefkurs 16.05.24
    ISIN: FR0012127173 · WKN: A14QXP · Frankreich

    Neueste Nachrichten

    OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective
    16.04.24 · globenewswire · OSE Immunotherapeutics
    OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi in Lung Cancer
    10.04.24 · globenewswire · OSE Immunotherapeutics
    OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology
    02.04.24 · globenewswire · OSE Immunotherapeutics
    OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update
    27.03.24 · globenewswire · OSE Immunotherapeutics
    OSE Immunotherapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial Evaluating Lusvertikimab in Patients with Ulcerative Colitis
    18.03.24 · Business Wire (engl.) · OSE Immunotherapeutics
    Fokus Aktien mit extremen Handelsvolumen am Mittwoch, den 28.02.2024
    28.02.24 · wO Chartvergleich · Dycom Industries
    OSE Immunotherapeutics to Host a Live Webcast to Discuss AbbVie Global Partnership
    28.02.24 · Business Wire (engl.) · OSE Immunotherapeutics
    AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
    28.02.24 · Business Wire (engl.) · OSE Immunotherapeutics
    OSE Immunotherapeutics Provides Update on Clinical Results With OSE-279 in Advanced Solid Tumors
    26.02.24 · Business Wire (engl.) · OSE Immunotherapeutics
    OSE Immunotherapeutics Highlights Clinical Portfolio Advancements and Provides 2024 Outlook
    19.01.24 · Business Wire (engl.) · OSE Immunotherapeutics
    OSE Immunotherapeutics and Nantes University Hospital Present Positive Interim Data Analysis from the FIRsT Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant
    11.12.23 · Business Wire (engl.) · OSE Immunotherapeutics
    OSE Immunotherapeutics Announces a Collaboration Agreement with GenDx for the Development of a Companion Diagnostic for Epitope-Based Cancer Vaccine Candidate Tedopi
    21.11.23 · Business Wire (engl.) · OSE Immunotherapeutics